Third ADC candidate with Synaffix’ technology enters clinic as Miracogen initiated Phase 1
Shanghai Miracogen’s ADC partnership with Synaffix is paying off as MRG-004A, an ADC designed to treat solid tumors, has entered US Phase 1/2 to treat solid tumors. It marks the third ADC candidate developed with Synaffix's Glycoconnect technology that has entered clinical development. MRG-004A is currently being developed for TF-positive advanced or metastatic solid tumors. Chinese Miracogen is responsible for the research, development, manufacturing and commercialization of the ADC product, while Synaffix is responsible for the manufacturing of components that are specifically related to its Glycoconnect and Hydraspace technologies. MRG-004A is an ADC targeting human tissue factor, conjugated using Glycoconnect site specific conjugation technology. It was selected for clinical development based on highly competitive efficacy and tolerability in preclinical studies compared to conventional ADC technology.